Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Exelon
Exelon 1.5 mg hard capsules Exelon 3.0 mg hard capsules Exelon 4.5 mg hard capsules Exelon 6.0 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-087793 · Präparat HOS-083555
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 552–1108 im Abschnitt
Wechselwirkungen · Exelon
Exelon 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 22
HOS-087827 · Präparat HOS-083555
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta- blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 78862f233afbcffbdeea1de1561f4b9c8b935afa56c5174b5a2005dd38afbc6b · Zeichen 552–1109 im Abschnitt
Wechselwirkungen · Exelon
Exelon 4.6 mg/24 h transdermal patch Exelon 9.5 mg/24 h transdermal patch Exelon 13.3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 39
HOS-087854 · Präparat HOS-083555
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 639–1195 im Abschnitt
Wechselwirkungen · Prometax
Prometax 1.5 mg hard capsules Prometax 3.0 mg hard capsules Prometax 4.5 mg hard capsules Prometax 6.0 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-090119 · Präparat HOS-084005
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 552–1108 im Abschnitt
Wechselwirkungen · Prometax
Prometax 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 20
HOS-090144 · Präparat HOS-084005
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta- blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 78862f233afbcffbdeea1de1561f4b9c8b935afa56c5174b5a2005dd38afbc6b · Zeichen 552–1109 im Abschnitt
Wechselwirkungen · Prometax
Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 35
HOS-090169 · Präparat HOS-084005
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 641–1197 im Abschnitt
Wechselwirkungen · Rivastigmine Sandoz
Rivastigmine Sandoz 1.5 mg hard capsules Rivastigmine Sandoz 3 mg hard capsules Rivastigmine Sandoz 4.5 mg hard capsules Rivastigmine Sandoz 6 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-122887 · Präparat HOS-095601
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic
agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T09:12:00Z · SHA-256 15f98a67c45ceb51925143ff48f1e7d8121d52a4a658b6281e33c989f7e1881d · Passage cc1d055f4b17075b4f2fc3a7d1057a8da7a88e906a27c2a6a453b7311ec19f40 · Zeichen 553–1109 im Abschnitt
Wechselwirkungen · Rivastigmine Sandoz
Rivastigmine Sandoz 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 20
HOS-122924 · Präparat HOS-095601
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic
agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T09:12:00Z · SHA-256 15f98a67c45ceb51925143ff48f1e7d8121d52a4a658b6281e33c989f7e1881d · Passage cc1d055f4b17075b4f2fc3a7d1057a8da7a88e906a27c2a6a453b7311ec19f40 · Zeichen 553–1109 im Abschnitt
Wechselwirkungen · Rivastigmine Actavis
Rivastigmine Actavis 1.5 mg hard capsules Rivastigmine Actavis 3 mg hard capsules Rivastigmine Actavis 4.5 mg hard capsules Rivastigmine Actavis 6 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-124105 · Präparat HOS-095787
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-13T13:08:00Z · SHA-256 2ee23f20fd86dbaec9fd1d934113d5a18e6d23f0ae5c24c65cb32fd7cb33a0f8 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 552–1108 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.